Cargando…

Prophylactic penehyclidine inhalation for prevention of postoperative pulmonary complications in high-risk patients: study protocol of a randomized controlled trial

BACKGROUND: Postoperative pulmonary complications (PPCs) are major causes of morbidity, mortality, and prolonged hospital stay in patients after surgery. Using effective strategies to prevent its occurrence is essential to improve outcome. However, despite various efforts, the incidence of PPCs rema...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Ting, Liang, Xin-Quan, Wang, Tong, Li, Wei-Ou, Li, Hui-Juan, Zhu, Sai-Nan, Wang, Dong-Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706155/
https://www.ncbi.nlm.nih.gov/pubmed/29183393
http://dx.doi.org/10.1186/s13063-017-2315-7
_version_ 1783282166688382976
author Yan, Ting
Liang, Xin-Quan
Wang, Tong
Li, Wei-Ou
Li, Hui-Juan
Zhu, Sai-Nan
Wang, Dong-Xin
author_facet Yan, Ting
Liang, Xin-Quan
Wang, Tong
Li, Wei-Ou
Li, Hui-Juan
Zhu, Sai-Nan
Wang, Dong-Xin
author_sort Yan, Ting
collection PubMed
description BACKGROUND: Postoperative pulmonary complications (PPCs) are major causes of morbidity, mortality, and prolonged hospital stay in patients after surgery. Using effective strategies to prevent its occurrence is essential to improve outcome. However, despite various efforts, the incidence of PPCs remains elevated in high-risk patients. Anticholinergic inhalation is used to reduce high airway resistance and improve pulmonary function; it may be helpful to decrease the risk of PPCs. Penehyclidine is a long-acting anticholinergic agent which selectively blocks M1 and M3 receptors. We hypothesize that, in high-risk patients, prophylactic penehyclidine inhalation may decrease the incidence of PPCs. METHODS: This is a randomized, double-blind, placebo-controlled trial with two parallel arms. A total of 864 patients at high risk of PPCs will be enrolled and randomized to receive prophylactic inhalation of either penehyclidine or placebo (water for injection). Study drug inhalation will be administered from the night (7 pm) before surgery until the second day after surgery, in an interval of every 12 hours. The primary outcome is the incidence of PPCs within 30 days after surgery. Secondary outcomes include the time to onset of PPCs (from end of surgery to first diagnosis of PPCs), the number of PPCs (indicates the number of diagnosed individual PPCs), the incidence of postoperative extrapulmonary complications, the length of stay in hospital after surgery, and the 30-day all-cause mortality. DISCUSSION: Results of the present study will provide evidence to guide clinical practice in using prophylactic inhalation of an anticholinergic to prevent PPCs in high-risk patients. TRIAL REGISTRATION: The study was registered prospectively in Chinese Clinical Trial Registry (www.chictr.org.cn, ChiCTR-IPC-15006603) on 14 May 2015 and retrospectively in ClinicalTrials.gov (NCT02644876) on 30 December 2015. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13063-017-2315-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5706155
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57061552017-12-05 Prophylactic penehyclidine inhalation for prevention of postoperative pulmonary complications in high-risk patients: study protocol of a randomized controlled trial Yan, Ting Liang, Xin-Quan Wang, Tong Li, Wei-Ou Li, Hui-Juan Zhu, Sai-Nan Wang, Dong-Xin Trials Study Protocol BACKGROUND: Postoperative pulmonary complications (PPCs) are major causes of morbidity, mortality, and prolonged hospital stay in patients after surgery. Using effective strategies to prevent its occurrence is essential to improve outcome. However, despite various efforts, the incidence of PPCs remains elevated in high-risk patients. Anticholinergic inhalation is used to reduce high airway resistance and improve pulmonary function; it may be helpful to decrease the risk of PPCs. Penehyclidine is a long-acting anticholinergic agent which selectively blocks M1 and M3 receptors. We hypothesize that, in high-risk patients, prophylactic penehyclidine inhalation may decrease the incidence of PPCs. METHODS: This is a randomized, double-blind, placebo-controlled trial with two parallel arms. A total of 864 patients at high risk of PPCs will be enrolled and randomized to receive prophylactic inhalation of either penehyclidine or placebo (water for injection). Study drug inhalation will be administered from the night (7 pm) before surgery until the second day after surgery, in an interval of every 12 hours. The primary outcome is the incidence of PPCs within 30 days after surgery. Secondary outcomes include the time to onset of PPCs (from end of surgery to first diagnosis of PPCs), the number of PPCs (indicates the number of diagnosed individual PPCs), the incidence of postoperative extrapulmonary complications, the length of stay in hospital after surgery, and the 30-day all-cause mortality. DISCUSSION: Results of the present study will provide evidence to guide clinical practice in using prophylactic inhalation of an anticholinergic to prevent PPCs in high-risk patients. TRIAL REGISTRATION: The study was registered prospectively in Chinese Clinical Trial Registry (www.chictr.org.cn, ChiCTR-IPC-15006603) on 14 May 2015 and retrospectively in ClinicalTrials.gov (NCT02644876) on 30 December 2015. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13063-017-2315-7) contains supplementary material, which is available to authorized users. BioMed Central 2017-11-28 /pmc/articles/PMC5706155/ /pubmed/29183393 http://dx.doi.org/10.1186/s13063-017-2315-7 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Study Protocol
Yan, Ting
Liang, Xin-Quan
Wang, Tong
Li, Wei-Ou
Li, Hui-Juan
Zhu, Sai-Nan
Wang, Dong-Xin
Prophylactic penehyclidine inhalation for prevention of postoperative pulmonary complications in high-risk patients: study protocol of a randomized controlled trial
title Prophylactic penehyclidine inhalation for prevention of postoperative pulmonary complications in high-risk patients: study protocol of a randomized controlled trial
title_full Prophylactic penehyclidine inhalation for prevention of postoperative pulmonary complications in high-risk patients: study protocol of a randomized controlled trial
title_fullStr Prophylactic penehyclidine inhalation for prevention of postoperative pulmonary complications in high-risk patients: study protocol of a randomized controlled trial
title_full_unstemmed Prophylactic penehyclidine inhalation for prevention of postoperative pulmonary complications in high-risk patients: study protocol of a randomized controlled trial
title_short Prophylactic penehyclidine inhalation for prevention of postoperative pulmonary complications in high-risk patients: study protocol of a randomized controlled trial
title_sort prophylactic penehyclidine inhalation for prevention of postoperative pulmonary complications in high-risk patients: study protocol of a randomized controlled trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706155/
https://www.ncbi.nlm.nih.gov/pubmed/29183393
http://dx.doi.org/10.1186/s13063-017-2315-7
work_keys_str_mv AT yanting prophylacticpenehyclidineinhalationforpreventionofpostoperativepulmonarycomplicationsinhighriskpatientsstudyprotocolofarandomizedcontrolledtrial
AT liangxinquan prophylacticpenehyclidineinhalationforpreventionofpostoperativepulmonarycomplicationsinhighriskpatientsstudyprotocolofarandomizedcontrolledtrial
AT wangtong prophylacticpenehyclidineinhalationforpreventionofpostoperativepulmonarycomplicationsinhighriskpatientsstudyprotocolofarandomizedcontrolledtrial
AT liweiou prophylacticpenehyclidineinhalationforpreventionofpostoperativepulmonarycomplicationsinhighriskpatientsstudyprotocolofarandomizedcontrolledtrial
AT lihuijuan prophylacticpenehyclidineinhalationforpreventionofpostoperativepulmonarycomplicationsinhighriskpatientsstudyprotocolofarandomizedcontrolledtrial
AT zhusainan prophylacticpenehyclidineinhalationforpreventionofpostoperativepulmonarycomplicationsinhighriskpatientsstudyprotocolofarandomizedcontrolledtrial
AT wangdongxin prophylacticpenehyclidineinhalationforpreventionofpostoperativepulmonarycomplicationsinhighriskpatientsstudyprotocolofarandomizedcontrolledtrial